Affiliation:
1. Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032
2. Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032
Abstract
Cefatrizine, a new orally administered cephalosporin, was tested against 400 clinical isolates. Cefatrizine had excellent activity against gram-positive cocci, inhibiting all except enterococci at minimal inhibitory concentrations below 1 μg/ml. Cefatrizine inhibited the majority of
Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis
, and
Salmonella
at concentrations below 12.5 μg/ml. Although cefatrizine was not hydrolyzed by many β-lactamases, it did not inhibit a number of strains of
Enterobacter, Serratia
, or indole-positive
Proteus
. Cefatrizine was more active than cephalothin or cephalexin against
E. coli, Klebsiella, Enterobacter, Citrobacter, Salmonella
, and
Shigella
. Its overall activity was less than that of cefoxitin against strains resistant to cephalothin, but its activity against cephalothin-susceptible strains was equivalent to that of cefamandole.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献